The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019

Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caracò, Alessandro Testori

Research output: Contribution to journalArticlepeer-review


The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treatment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected their respective personal approach.
Original languageEnglish
Pages (from-to)171
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Apr 16 2020


  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • BRAF inhibitor
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Staging immunotherapy
  • Targeted therapy


Dive into the research topics of 'The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019'. Together they form a unique fingerprint.

Cite this